Novartis Claims New Drugs, Pipeline Will Fuel Growth, Not M&A
Executive Summary
Novartis sees itself engaging in only modest M&A activity to avoid over-paying for targets - and will rely on newly launched drugs and promising external targets to grow sales.
You may also be interested in...
First In MS: Fingolimod Nears Market For Relapsing MS In Children, Adolescents
Per initial data from Novartis's PARADIGMS study in adolescents and children, Gilenya is the first therapy shown to reduce MS relapses in younger patients in a controlled late-stage clinical study, and Novartis says it will prepare marketing submissions for the additional indication after fully analyzing the data.
Novartis' Rydapt: Two Indications, Two Prices
Rydapt was approved by the US FDA for the one-third of patients with acute myeloid leukemia who test positive for a FLT3 mutation, which is associated with a poorer prognosis, and for advanced systemic mastocytosis.
Heartache For Novartis As Serelaxin Failure Ups Pressure On Entresto
Novartis's latest Phase III study of serelaxin has failed, deleting a significant chunk of forecasted revenue that analysts had attributed to the heart failure drug candidate.